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The Sp/Kru¨ppel-like factor (Sp/Klf) family is comprised of around 25 zinc finger transcription factors that
recognize CACCC boxes and GC-rich elements. We have investigated basic Kru¨ppel-like factor (Bklf/Klf3) and
show that in erythroid tissues its expression is highly dependent on another family member, erythroid
Kru¨ppel-like factor (Eklf/Klf1). We observe that Bklf mRNA is significantly reduced in erythroid tissues from
Eklf-null murine embryos. We find that Bklf is driven primarily by two promoters, a ubiquitously active GC-rich
upstream promoter, 1a, and an erythroid downstream promoter, 1b. Transcripts from the two promoters
encode identical proteins. Interestingly, both the ubiquitous and the erythroid promoter are dependent on Eklf
in erythroid cells. Eklf also activates both promoters in transient assays. Experiments utilizing an inducible
form of Eklf demonstrate activation of the endogenous Bklf gene in the presence of an inhibitor of protein
synthesis. The kinetics of activation are also consistent with Bklf being a direct Eklf target. Chromatin
immunoprecipitation assays confirm that Eklf associates with both Bklf promoters. Eklf is typically an
activator of transcription, whereas Bklf is noted as a repressor. Our results support the hypothesis that
feedback cross-regulation occurs within the Sp/Klf family in vivo.
The mammalian Sp/Kru¨ppel-like factor (Sp/Klf) family con-
sists of 9 Sp and 17 Klf subfamily proteins (78, 88). Sp/Klfs bind
GC-rich elements and related CACCC sequences in DNA by
means of three tandem C2H2 zinc fingers found at or near their
C termini (27, 46, 75). While this zinc finger domain is highly
conserved among family members (85), other regions of the
proteins are not. Accordingly, although they recognize similar
DNA-binding sites, some Sp/Klfs, such as erythroid Klf (Eklf)/
Klf1, serve predominantly as activators (56); others, such as
basic Klf (Bklf)/Klf3, are regarded as transcriptional repressors
(84). It is possible, however, that many and perhaps all Sp/Klfs
function as either activators or repressors, depending on pro-
moter and cellular context (38). Sp/Klf proteins have been
found to play critical roles in a diversity of biological processes
(9, 21), including erythropoiesis (8, 53, 63, 68, 87, 91), adipo-
genesis (7, 58, 64), and carcinogenesis (10, 29, 61, 90).
Many Sp/Klfs, such as Sp1, are broadly expressed, whereas
others, such as Eklf, exhibit more-limited expression patterns.
Eklf is so named because its expression is restricted mainly to
erythroid cells, but it is also detectable in macrophages and
mast cells (52, 56). It is a potent transcriptional activator rec-
ognized for binding CACCC boxes and related sequences that
fall into the general consensus sequence 5-NCNCNCCCN-3
(27). These motifs are found in the regulatory regions of many
erythroid genes (27, 56, 71). The adult -globin promoter, for
instance, contains an Eklf recognition site that is critical for
-globin expression (23, 27). As a result, Eklf knockout mice
die at around embryonic day 15 (E15) with a severe -globin
deficiency (63, 68).
Efforts have been made to rescue the Eklf-null phenotype by
the overexpression of human A-globin. However, despite a
correction of the globin chain imbalance, the null mice still die
in utero due to hemolysis (67). This result suggests that other
critical Eklf target genes exist. Recently, several genes have
been shown to be underexpressed in Eklf-null fetal liver (24,
33, 70). These include the genes for -hemoglobin stabilizing
protein (Ahsp), which binds and stabilizes free -hemoglobin
and prevents its cytotoxic precipitation, and dematin, a cyto-
skeletal protein required for membrane integrity in erythro-
cytes. Numerous other Eklf target genes have been proposed
from studies of differential expression in Eklf-null fetal liver.
However, in many cases, it is uncertain whether these are
direct targets or whether they are genes that are indirectly
influenced by hypoxia, incomplete erythroid maturation, or
skewed cellular heterogeneity in the Eklf-null mice.
Work with physiologically relevant cell lines has been em-
ployed to circumvent these complexities. The B1.6 cell line
(17), for instance, has allowed for the validation of Ahsp and
dematin as direct targets of Eklf (33). This line was generated
by immortalizing E14.5 Eklf-null fetal liver erythroid progeni-
tors using the J2 retrovirus. The cells were then rescued using
a transgene encoding Eklf fused to the ligand-binding domain
of the estrogen receptor Eklf-ER (17, 50). A mutant form of
the ER was used, so that the fusion would respond to the
synthetic steroid tamoxifen but not to estrogen, which may be
present in culture medium (50). The addition of tamoxifen
results in the accumulation of Eklf-ER in the nucleus, the
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activation of Eklf target genes, and the subsequent hemoglo-
binization and terminal differentiation of the cells (17).
It has long been noted that there are several apparently
abundant CACCC box-binding proteins present in erythroid
cells, in addition to Eklf and the ubiquitous protein Sp1 (19,
32). A cDNA-encoding Bklf was isolated using probes specific
for the zinc finger domain of Eklf and Sp1 and relaxed-strin-
gency hybridization with a mouse erythroleukemia (MEL)
cDNA library (20). Bklf is found in a wide range of tissues and
cell types but is particularly abundant in hematopoietic tissue
(20). Like Eklf, Bklf binds CACCC motifs in preference to GC
boxes (20). Bklf has been shown to bind in vitro the promoter
CACCC elements of many erythroid genes, such as adult -glo-
bin, fetal A-globin, Gata-1, carbonic anhydrase I, porphobilino-
gen deaminase (Pbgd), and pyruvate kinase (20, 66). The
CACCC-binding activity of Bklf is more readily detected in
yolk sac and fetal liver than that of Eklf (20), suggestive of a
potential role in hematopoiesis. The phenotype of Bklf-null
mice, however, is complex, consistent with Bklf being broadly
expressed. Precise target genes and biological roles for the
protein have been difficult to define (unpublished results).
Functionally, Bklf was initially shown to be a transcriptional
activator. However, transactivation was observed only with
high levels of Bklf and was not as strong as Eklf-mediated
activation (20). Bklf has since been established as a potent
transcriptional repressor in many systems (66, 84, 86). The
protein is highly basic, hence the name basic Kru¨ppel-like
factor, and it includes a repression domain that contains a
Pro-Val-Asp-Leu-Thr motif through which Bklf interacts with
the corepressor C-terminal binding protein (84).
It has previously been noted that Bklf protein levels are
reduced in the fetal liver (erythroid tissue) but are unaffected
in the fetal brain (nonerythroid) in Eklf/ mice (20, 68).
Whether this is a direct or indirect effect has not previously
been explored. We have now found that Bklf expression is
driven from two promoters. The upstream promoter, 1a, is
active in a wide range of tissues, while the downstream pro-
moter, 1b, which gives rise to a novel Bklf transcript (but
encodes an identical protein), is active predominantly in ery-
throid tissues. We find that transcripts from both promoters
are underexpressed in Eklf-null fetal liver. Activation of both
promoters by Eklf is observed for heterologous cells in tran-
sient transfection experiments. Chromatin immunoprecipita-
tion experiments confirm that Eklf-ER directly binds to both
promoters in B1.6 cells. The induction of Eklf-ER activates the
endogenous downstream erythroid promoter 1b in the B1.6
line but, unexpectedly, no activation of the upstream promoter
is observed with this system. The kinetics of the induction of
promoter 1b and the observation that induction occurs in the
presence of an inhibitor of protein synthesis further suggest
that Bklf is a direct Eklf target gene.
We have also examined several other Klf genes and, inter-
estingly, find that Tieg/Klf10 is also activated by Eklf-ER in
B1.6 cells in the presence of a protein synthesis inhibitor and is
underexpressed in Eklf-null fetal liver. These results reveal
cross-regulation of the Klf subfamily in erythroid cells.
MATERIALS AND METHODS
Genotyping. Genotyping of the Eklf-null mice was performed as described
previously (33).
RNA extraction. E14.5 fetal livers and tissue sections (up to 140 mg) from 13-
to 16-week-old female C57BL/6 mice (68) were freshly homogenized for RNA
extraction after washing with phosphate-buffered saline (Sigma, St. Louis, MO).
Adult mice were sacrificed by cervical dislocation to avoid indirect effects caused
by terminal anesthesia. Total RNA was extracted with TRI REAGENT (Sigma)
per the supplier’s protocol but with an additional centrifugation step at 12,000 
g for 10 min at 4°C following homogenization to reduce contamination by
genomic DNA. RNA was then cleaned up with RNeasy kits (QIAGEN Pty. Ltd.,
Victoria, Australia) and was subsequently subjected to DNase treatment with a
DNA-free kit (Ambion, Austin, TX) as instructed by the supplier.
Real-time RT-PCR. Up to 5 g of RNA was used as a template for cDNA
synthesis primed by random hexamers with a SuperScript III First Strand cDNA
Synthesis kit (Invitrogen, Carlsbad, CA). Quantitative real-time reverse tran-
scription (RT)-PCR was performed with SYBR Green PCR Master Mix by using
an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City,
CA). Approximately 10 ng of cDNA, as estimated by UV spectrophotometry,
was used in each RT-PCR. Samples were normalized with respect to 18S rRNA
levels. Reactions containing serial dilutions of gel-purified amplicon were in-
cluded in each RT-PCR run in order to construct standard curves for relative
quantification. Minus RT and no-template reactions were included as negative
controls. The analysis of real-time PCR data was done with ABI Prism 7000
sequence detection system software (version 1.1).
Real-time PCR primers. Paired primers were designed with PrimerExpress
software (Version 2.0) (Applied Biosystems) to cross, where possible, exon-exon
boundaries to prevent amplification of any contaminating genomic DNA. Primer
sequence specificity was checked using the Basic Local Alignment Search Tool
(BLAST; http://www.ncbi.nlm.nih.gov/BLAST) (4). For each primer set, optimal
reaction concentrations, ranging between 200 nM and 600 nM, were determined.
The sequences of forward and reverse primers used are as follows: 18S, 5-CA
CGGCCGGTACAGTGAAAC-3 (forward) and 5-AGAGGAGCGAGCGAC
CAA-3 (reverse); Bklf exons 4/5, 5-GAAATGTCACCCCCTTTAATGAAC-3
and 5-CACGATGACGGAAGGATGGT-3; Bklf exons 1a/2, 5-CGGGCCTG
GGTTTCTTG-3 and 5-GATCAAACATGAGCATCCTTTCAG-3; Bklf ex-
ons 1b/2, 5-GGTGGAATTCTGTTCAGGTCAAC-3 and 5-CCACGCCTTC
TAGGGTGTTCT-3; Klf10, 5-GCAGCCAACCATGCTCAAC-3 and 5-CCC
CTCTCTGGGCTTTTCAG-3; Klf13, 5-CGAGAAAGTTTACGGGAAATCT
TC-3 and 5-CAGGCGAAAGGCCTCTCA-3; and Klf16, 5-TCACACCTGC
GGACTCACA-3 and 5-CAGAACGGGCGAACTTCTTG-3.
EMSAs. Nuclear extracts were prepared and electrophoretic mobility shift
assays (EMSAs) were carried out as described previously (20). Anti-Eklf and
anti-Bklf antibodies have been described previously (20). Anti-Sp1 and anti-Sp3
antibodies were supplied by Santa Cruz Biotechnology, Santa Cruz, CA.
Oligonucleotides used in the synthesis of radiolabeled probes are as follows:
mouse -major globin CACCC probe, 5-TAGAGCCACACCCTGGTAAG-3
and 5-CTTACCAGGGTGTGGCTCTA-3; Bklf promoter 1b CACCC probe,
5-AGTACTGGGTGTGGGCAGAATCTTATCTGAAGCT-3 and 5-AGCT
TCAGATAAGATTCTGCCCACACCCAGTACT-3.
5 RACE. One g MEL total RNA was used as a template for first-strand
cDNA synthesis with a SMART rapid amplification of cDNA ends (RACE)
cDNA amplification kit (BD Biosciences, Palo Alto, CA) as instructed by the
supplier. RACE PCR was performed as described in the Advantage 2 Polymer-
ase kit manual (BD Biosciences) with an additional five repetitions of the final
cycle. For each reaction, cDNA synthesized from 	20 ng total RNA was used. 5
RACE was primed with an oligonucleotide, 5-TCCACCGGCTCCACCTGTA
TCCC-3, specific for the third exon of Bklf. Confirmatory 5 RACE PCR was
conducted with a primer, 5-GGGACTGGATCAAACATGAGCATCCTT-3,
specific for exon 2 of Bklf. 3 RACE primers, specific for Bklf exon 1b, were as
follows: 5-ATTGCATCCCATCTGAAGCCAAGC-3 and 5-GAGAGGCAC
AGATTCGGAAATATCCG-3. RACE products were resolved by 2% agarose
gel electrophoresis and purified with Spin-X centrifuge tube filters (Trace Bio-
sciences, Castle Hill, New South Wales, Australia). Products were cloned into
the pGEM-T Easy vector (Promega Corporation, Madison, WI) and subjected to
blue-white colony selection as instructed by the supplier. Automated sequencing
was performed by the Automated DNA Sequencing Service, Sydney University
Prince Alfred Macromolecular Analysis Centre.
Primer extension. Primer extension was carried out as previously described
(5). RNA from MEL and NIH 3T3 cells was primed with an oligonucleotide
specific for Bklf exon 1a, 5-CCATCGATGGCGGCCAAGAAACCCAGGCC
CGGCT-3, and was extended with avian myeloblastosis virus reverse transcrip-
tase (Promega).
Cell culture. MEL, NIH 3T3, and COS cells were cultured at 37°C and 5%
CO2 in Dulbecco’s modified Eagle’s medium (low glucose) supplemented with
10% (vol/vol) heat-inactivated fetal calf serum and 1% (vol/vol) penicillin, strep-
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tomycin, and glutamine solution (Gibco-BRL Life Technologies, Grand Island,
NY). Drosophila melanogaster Schneider line 2 (SL-2) cells were grown at 24°C
in Schneider medium (Gibco) supplemented with 10% (vol/vol) heat-inactivated
fetal calf serum and 1% (vol/vol) penicillin, streptomycin, and glutamine solu-
tion. B1.6 erythroblast cells were cultured as described previously (17). Cells
were induced by the addition of 1 mM 4-hydroxytamoxifen (in ethanol) to a final
concentration of 100 nM. As a negative control, ethanol was added to a final
concentration of 0.0001% (vol/vol). RNA was extracted as described above at
48 h postinduction or at 0, 2, 4, 8, and 24 h postinduction for the time course
study. For translation inhibition analyses, cycloheximide (made up in ethanol)
was added to subconfluent cells to a final concentration of 5 g/ml. Thirty
minutes later, cells were induced with 4-hydroxytamoxifen or with ethanol as a
negative control as described above. RNA was extracted 8 h after tamoxifen
induction to avoid cell death due to cycloheximide cytotoxicity.
ChIP. Chromatin immunoprecipitation (ChIP) assays were conducted with
Eklf and preimmune serum as previously reported (33, 34, 49). Immunopre-
cipitated DNA was analyzed by real-time PCR using the following primer sets:
Bklf promoter 1a, 5-GCTGCCTCCACCCAAGTG-3 and 5-ACCAACTCTG
GGCAGTCACAT-3; Bklf promoter 1b, 5-CTGGGTGTGGGCAGAATCT
T-3 and 5-GCCAGGGCGAGTCCAACT-3; negative control region approx-
imately 10 kb upstream of Bklf, 5-GCCTGCGGGAGGTGATTAC-3 and 5-
TTCTTGAAGCAAAGCCAAGAATATC-3. -major globin and nectin control
primers have been described previously (33).
Vectors and cloning of the Bklf promoters. To clone Bklf promoter 1a, a
129SVJ mouse genomic library in Lambda FIX II vector (Stratagene, La Jolla,
CA) was screened as suggested by the supplier. An approximately 500-bp se-
quence encompassing a portion of intron 1 and of exon 2 of Bklf was radiolabeled
with [-32P]dCTP (1.7 106 cpm/ml) and was used to probe the library. A 2.3-kb
NotI/NotI fragment containing exon 1a plus approximately 1.8 kb of upstream
sequence and 400 bp of intron 1 was obtained from a positively identified clone
and then subloned into pBlueScript KS II (Stratagene) to create pBKS-Bklfprom1a.
Two fragments (189 to 89 and 532 to 89) were amplified from pBKS-
Bklfprom1a by PCR with the forward primers 5-ATTAGGTACCGGCTCCCAGCC
TCTACTTACCC-3 and 5-ATTAGGTACCCGGAGCGCTCAGGCG-3, respec-
tively, and the reverse primer 5-ATTAAAGCTTAACCCAGGCCCGGCTC-3. The
fragments were then subcloned into KpnI/HindIII pGL4.10[luc2] (Promega), a promot-
erless vector, to create pGL4.10[luc2]-Bklfprom1a(18989) and pGL4.10[luc2]-
Bklfprom1a(53289). To clone Bklf promoter 1b, 286-bp (225 to 61), 190-bp
(129 to61), 182-bp (121 to61) and 96-bp (35 to61) fragments were ampli-
fied from C57BL/6 genomic DNA (supplied by Richard Pearson, School of Molecular
and Microbial Biosciences, Sydney, Australia) by PCR using the forward primers 5-A
TTAGGTACCTTGGAAAGCTGGAGAGAGTC-3, 5-ATTAGGTACCGGGTG
TGGGCAGAATC-3, 5-ATTAGGTACCGCAGAATCTTATCTGAAGCTATG-
3, and 5-ATTAGGTACCGCAGAAAAGTAAAATTGGGTG-3, respectively, and
the reverse primer 5-ATTAAAGCTTTTCATTGCTTGGCTTCAGATG-3. The
fragments were subcloned into KpnI/HindIII pGL4.10[luc2] to form pGL4.10[luc2]-
Bklfprom1b(22561), pGL4.10[luc2]-Bklfprom1b(12961), pGL4.10[luc2]-
Bklfprom1b(12161), and pGL4.10[luc2]-Bklfprom1b(3561). pPac and pPac-Eklf
were kindly provided by Menie Merika and Stuart Orkin (Harvard Medical School,
Boston, MA). pSG5-Eklf was generously supplied by James Bieker (Mount Sinai
School of Medicine, New York, NY).
Transactivation assays. SL-2 cells were transfected in six-well plates using the
calcium phosphate method (72). Zero, 10, 50 or 100 ng pPac-Eklf (supplemented to
a total 100-ng vector with pPac) was transfected along with 1 g pGL4.10[luc2],
pGL4.10[luc2]-Bklfprom1a(18989), pGL4.10[luc2]-Bklfprom1a(53289), pGL4.
10[luc2]-Bklfprom1b(22561), pGL4.10[luc2]-Bklfprom1b(12961), pGL4.10
[luc2]-Bklfprom1b(12161), or pGL4.10[luc2]-Bklfprom1b(3561). For all
transfections, 10 ng pGL4.74[hRluc/TK] (Promega) was included as a transfec-
tion control. Forty-eight hours posttransfection, cells were lysed and assayed for
luciferase activity by using a dual-luciferase reporter assay system (Promega).
MEL cells were transfected in six-well plates with 1 g of the pGL4.10[luc2]
constructs and 10 ng pGL4.74[hRluc/TK] and were harvested 48 h later. Trans-
fection was achieved with Tfx-50 reagent (Promega) per the manufacturer’s
instructions. In all cases, reporter activity was normalized with respect to Renilla
luciferase levels.
Overexpression of Eklf in COS cells. Plates (100 mm) of COS cells, at 50%
confluence, were transfected with 5 g pSG5-Eklf (or 5 g pMT3 as a negative
control) using FuGENE6 (Roche Diagnostics) as instructed by the manufac-
turer. The medium was changed 48 h following transfection, and cells were
harvested for nuclear extracts 24 h later as described previously (20).
Bioinformatics. GenBank cDNA and genomic searches were conducted using
the BLAST algorithm (4) at the NCBI website (http://www.ncbi.nlm.nih.gov
/BLAST). Full-length Bklf cDNAs from the DDBJ and GenBank were obtained
from nucleotide searches (August 2006) at the NCBI website (http://www.ncbi
.nlm.nih.gov). Additional start points of transcription were identified (August
2006) from oligonucleotide-cap cDNA entries at the Database of Transcriptional
FIG. 1. Bklf protein is diminished in Eklf-null murine fetal liver. (A) EMSA showing the identity of proteins found in erythroid cells which
recognize the -major globin promoter CACCC box. MEL cell nuclear extracts were allowed to bind to a radiolabeled probe containing the -major
globin promoter CACCC box in the presence of either preimmune serum or an antibody specific for Eklf, Bklf, Sp1, and/or Sp3. (B) EMSA analysis
of murine fetal liver nuclear extracts prepared from E14.5 Eklf-null and heterozygous (denoted below each lane) littermates. Lane 1 contains the
-major globin CACCC probe alone. Bklf and Eklf bands were confirmed by antibody supershifting. All lanes that lack either Eklf- or Bklf-specific
antibody (Eklf or Bklf) contain preimmune serum as a control.
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Start Sites (DBTSS; http://dbtss.hgc.jp/). Vertebrate conservation analyses were
performed with the University of California—Santa Cruz (UCSC) Genome
Browser (February 2006; http://genome.ucsc.edu/) using the mouse (mm8) ge-
nome assembly (44).
Nucleotide sequence accession number. A full-length Bklf cDNA entry con-
taining exon 1b has been submitted to GenBank (accession number DQ981866).
RESULTS
Bklf mRNA is reduced in Eklf-null cells. Several studies have
employed a probe containing the critical CACCC box of the
-major globin promoter in EMSAs to elucidate DNA-binding
proteins in erythroid cells (20, 32). The major CACCC-binding
activities detected include those of Sp1, Sp3, Eklf, and Bklf
(Fig. 1A). While the antibodies for Sp1 and Sp3 produce some
nonspecific inhibition of binding of other proteins, the anno-
tation of Sp1 and Sp3 in Fig. 1A is consistent with previous
identifications of these prevalent CACCC-binding factors (12,
31). Interestingly, when E14.5 Eklf/ fetal liver extracts are
examined, the DNA-binding activity of Bklf, but not that of
Sp1 or Sp3, is reduced (Fig. 1B). This result is in accordance
with previous observations, including Western blot experi-
ments, that show that Bklf protein levels are diminished in
Eklf-null fetal liver but not in nonerythroid tissues (20). These
results raise the possibility that Bklf is directly or indirectly
dependent on Eklf for its expression, stability, or activity in
erythroid cells.
Eklf is known to be a potent activator of transcription. We
first investigated whether Bklf’s dependence on Eklf is ob-
served at the mRNA level. RNA from E14.5 livers of Eklf/,
Eklf/, and wild-type murine fetuses was analyzed by real-
time RT-PCR using Bklf specific primers. Bklf transcripts were
underrepresented in Eklf/ fetal livers compared to the fetal
livers of Eklf/ and wild-type littermates (see Fig. 5C). In
accordance with this result, a recent microarray study on genes
that are differentially expressed in Eklf/ fetal liver also iden-
tified Bklf as such a downregulated gene, although this result
was not further validated (33). In addition, Bklf mRNA is
diminished in Eklf/ compared to wild-type fetal liver, sug-
gestive of dose dependency. Taken together, these data suggest
that Eklf is required for the direct or indirect activation of the
Bklf gene at the transcriptional level.
Identification of a novel Bklf leader exon, 1b. Bklf’s expres-
sion is highly dependent on Eklf in erythroid tissue, yet Bklf
mRNA is also expressed in other tissues, for instance, the fetal
head and the adult lung, where Eklf is not abundant (20).
Many genes have multiple promoters that allow their expres-
sion in a variety of different biological contexts (6). We hy-
FIG. 2. Characterization of the transcriptional start sites of the alternative exons of Bklf. (A) 5 RACE from MEL cDNA generates two distinct
bands which represent transcripts containing different lengths of the novel Bklf exon 1b. (B) Primer extension of Bklf mRNA using a primer specific
for Bklf exon 1a. Lanes 1 and 2 contain primer-extended total RNA from MEL cells and NIH 3T3 cells, respectively. Lane 3 contains yeast tRNA
as a negative control. Arrows indicate the two major start points of transcription for Bklf exon 1a. (C) A schematic of the murine Bklf locus showing
the relative positions of the two alternative first exons, 1a and 1b. Exons are denoted by gray boxes. The ATG start codon is also shown.
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pothesized that Bklf may utilize several promoters to achieve
its broad expression profile.
To explore this possibility, we used 5 RACE with a primer
targeted to exon 3 of Bklf. Two distinct fragments were ampli-
fied from MEL cell RNA (Fig. 2A) and were subsequently
cloned into pGEM-T Easy vector and sequenced. The two
fragments were identical, with the exception that one con-
tained an additional 31 base pairs at its 5 end (Fig. 3). As
anticipated, this fragment contained a portion of exon 3 (up to
the RACE primer) and exon 2, but it also contained an alter-
native first exon which differed from the previously published
leader exon of Bklf (RefSeq accession number NM_008453;
42) (Fig. 3). A BLAST analysis of the mouse genome revealed
that this novel first exon, hereby named exon 1b, lies within the
first intron of Bklf (Fig. 2C). 3 RACE confirmed that tran-
scripts containing exon 1b extend to include all the exons of the
gene (data not shown). A USCS Genome Browser analysis of
the putative promoter region immediately upstream of this
novel exon revealed a high level of conservation across a wide
range of divergent vertebrates including the chicken (Gallus
gallus) and the frog (Xenopus tropicalis) (data not shown). This
result supports the view that the novel promoter (1b) is of
functional importance. The two identified promoters (1a and
1b) generate transcripts that contain a single variant leader
exon (exon 1a or 1b) and five common downstream exons. The
AUG start codon lies within exon 2; hence, both transcripts
encode the same Bklf protein. The sequence of this novel Bklf
cDNA was submitted to GenBank.
We carried out additional experiments to further define the
start points of transcription. 5 RACE investigations using a
number of Bklf-specific primers consistently yielded fragments
exhibiting the two exon 1b putative transcription start sites
shown in Fig. 3 (data not shown). A single clone was identified,
however, which contained an additional 64 base pairs of non-
coding 5 sequence, suggestive of a weak upstream transcrip-
tional start site (Fig. 3).
Despite the frequent detection of 5 RACE products contain-
ing exon 1b, no products were found to contain the previously
identified first exon (1a), which is present in the majority of Bklf
cDNAs lodged at the DDBJ and GenBank. Their absence is
possibly due to the high GC content (approximately 77%) of exon
1a compared to that of exon 1b (approximately 46%), which the
RACE polymerase may have difficulty reading through. There-
fore, we employed primer extension, using a primer specific for
exon 1a, to determine the start sites of transcription for this
upstream promoter. In this way, two major transcription start sites
were identified (Fig. 2B and Fig. 3). An analysis of cDNA entries
lodged at DDBJ, GenBank, and the DBTSS revealed multiple
other proximal start sites (Fig. 3). This result suggests that pro-
moter 1a is a typical GC-rich promoter that exhibits numerous
start sites of transcription.
Bklf promoter 1b is active in erythroid tissues. To investi-
gate whether the two identified Bklf promoters have distinct
expression patterns, we examined the levels of mRNA they
produced in a range of adult murine tissues. Real-time RT-
PCR primers were designed to amplify regions crossing the
exon 1a/2 and exon 1b/2 boundaries, respectively. This allowed
discrimination between the two different transcripts and also
FIG. 3. The sequence of Bklf exon 1a (A) and exon 1b (B) and their flanking genomic regions. Note that approximately 8.3 kb of intron 1 has
been omitted. Exons are written in boldface type, and their transcriptional start sites, as determined by results shown in Fig. 2A and B, are denoted
by triangles. For each exon, the 5-most position of these start sites has been designated position 1. For exon 1b, an upstream transcriptional start
site that was infrequently detected by 5 RACE cloning is indicated with a boldface underline. For exon 1a, other putative transcription start sites
are underlined. These transcription start sites were inferred from full-length cDNA entries in GenBank (DDBJ accession numbers AK007959 [42],
AK157576, AK143838, and AK010713 [14, 41]; GenBank accession numbers BC116938 and BC119214 [77]) and from queries of the DBTSS (clone
names BY338164, BY724103, BY707959, BY742654, BY732683, BY732370, BY188922, BY062971, and BB628801 [45, 80]). Motifs that precisely
fit the Eklf binding consensus of 5-NCNCNCCC-3 (or its reverse complement) are boxed. The putative Gata-binding site in promoter 1b is
underlined.
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reduced the amplification of any trace amounts of contaminat-
ing genomic DNA. Transcripts from promoter 1a were found
ubiquitously (Fig. 4A). In contrast, transcripts containing exon
1b were found at high levels in the bone marrow and spleen
(Fig. 4B). Interestingly, Eklf’s expression is restricted to these
two hematopoietic organs (56). This result raised the possibil-
ity that promoter 1b might be dependent on Eklf and may
account for the reduction in Bklf mRNA observed with the
Eklf/ fetal livers. Quantitative assays using known amounts
of amplicon as template suggest that levels of the two Bklf
transcripts are roughly equivalent in erythroid tissue (data not
shown).
Bklf promoters 1a and 1b are dependent on Eklf in erythroid
cells. Given the restricted expression of transcripts containing
exon 1b (Fig. 4B), we reasoned that promoter 1b might be
highly dependent on Eklf and that its inactivity might contrib-
ute to the reduction in Bklf protein levels in the Eklf/ fetal
liver. We found exon 1b transcripts at approximately 30-fold
lower levels in Eklf/ than in wild-type fetal livers (Fig. 5B).
Interestingly, transcripts containing exon 1a that arise from the
ubiquitous promoter were found at approximately 10-fold
lower levels in the null fetal livers (Fig. 5A). This suggests that
both promoter 1b and, to a lesser extent, promoter 1a are
activated by Eklf. It should be noted, however, that Eklf is
clearly not crucial for expression from promoter 1a, as evi-
denced by its ubiquitous activity (Fig. 4A).
Eklf activates both Bklf promoters in transactivation assays.
To further explore the possibility that Eklf can activate tran-
scription from both promoters, we first performed transactiva-
tion experiments with Drosophila SL-2 cells, which are often
used to examine Klf proteins since they lack CACCC-binding
activity compared to mammalian cells (18). Fragments of both
Bklf promoters were cloned into the promoterless reporter
construct pGL4.10[luc2]. Bklf promoter 1a is GC rich and
contains many elements that fit the Eklf-binding consensus
sequence of 5-NCNCNCCCN-3 (Fig. 3). A 278-bp proximal
promoter region from 189 to 89 that contains several ca-
nonical Eklf recognition sites was activated slightly in the pres-
ence of Eklf (Fig. 6A). An extended promoter element (532
to 89) showed higher activation by Eklf, thus suggesting that
CACCC boxes upstream of 189 contribute to Eklf activation
(Fig. 6A). We also tested promoter 1b and found that the
region225 to61 is potently activated by Eklf (Fig. 6B). This
region contains three canonical Eklf recognition sites. A trun-
cated fragment (129 to 61) which retains all of these
CACCC sites is activated by Eklf to a similar degree (Fig. 6B).
In particular, one of the potential Eklf-binding sites (123 to
129) is identical to the critical -major globin promoter
CACCC box, which is bound by Eklf in vivo. Deleting this
motif results in a 
50% reduction in promoter activity in
response to Eklf (Fig. 6B, compare the 129 to 61 construct
with the 121 to 61 construct). In addition, EMSA analysis
demonstrated that Eklf can bind this Bklf promoter 1b
CACCC box (Fig. 6C). Lastly, a further truncated promoter
construct (35 to 61), which contains only one of the three
canonical Eklf-binding sites, was found not to be activated by
FIG. 4. The downstream Bklf promoter is active predominantly in hematopoietic tissue. The levels of the two Bklf transcripts in murine tissues
were determined by quantitative real-time RT-PCR. (A) Levels of Bklf transcripts generated from the upstream promoter and containing exon 1a.
(B) Levels of Bklf mRNA arising from the downstream promoter and containing exon 1b. All values were normalized to 18S rRNA levels. WAT,
white adipose tissue.
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Eklf (Fig. 6B). This implies that the 3-most CACCC box (3
to 9) is not sufficient for Eklf activation of Bklf promoter 1b.
In addition, all promoter 1a and 1b constructs that displayed
Eklf-mediated activation in SL-2 cells were also active in MEL
cells (data not shown); the MEL cell line expresses Eklf (Fig.
1A). Taken together, these results corroborate the data pre-
sented here that both Bklf promoters, particularly promoter
1b, are responsive to Eklf.
Eklf-ER activates the endogenous Bklf promoter 1b in B1.6
cells. To investigate the dependence of Bklf on Eklf in a more
physiological system, the B1.6 cell line was used. The B1.6 line
is an erythroid cell line derived from Eklf-null knockout mice
into which a transgene encoding a tamoxifen-inducible
Eklf-ER protein has been introduced (17, 50). Real-time RT-
PCR analysis demonstrated that, prior to activation of Eklf-ER
by tamoxifen, transcripts from promoter 1a were undetectable,
while mRNA from promoter 1b was at a trace level (Fig. 7A).
Following induction, transcripts from promoter 1a remained
undetected while promoter 1b was activated strongly. cDNA
levels of readily detectable Klfs, such as Klf13 and Klf16, which
were used as controls, displayed no change upon induction.
This result further provides strong evidence that promoter 1b
is activated, either directly or indirectly, by Eklf. Promoter 1a,
on the other hand, appears to be nonresponsive to Eklf-ER in
this cellular system.
We also examined other Klfs. Interestingly, Klf10 showed an
approximately eightfold increase in expression upon induction
(Fig. 7A). This result corroborates a previous microarray ob-
servation that Klf10 levels increase upon Eklf-ER induction
(33). Klf10 transcripts were also found to be reduced approx-
imately fourfold in Eklf-null compared to wild-type fetal liver
(Fig. 7B). This result further suggests that Klf10 is also regu-
lated by Eklf in eythroid cells, although not to the extent that
is observed for Bklf (compare Fig. 5).
Eklf-ER activates Bklf promoter 1b in the presence of cyclo-
heximide. It was possible that Eklf-ER was indirectly activating
Bklf via some intermediate downstream targets. We investi-
gated this possibility by exposing B1.6 cells to cycloheximide, a
translation inhibitor, prior to and during induction with tamox-
ifen. Due to the cytotoxicity of cycloheximide, cells were har-
vested 8 h (rather than 48 h) after induction. Activation of
promoter 1b occurred in induced cells in the presence of cy-
cloheximide, suggesting that the Bklf gene is a direct target of
Eklf (Fig. 8A). In addition, Klf10 mRNA was also upregulated
by Eklf-ER in the presence of cycloheximide, although to a
lesser degree than Bklf, thus suggesting that it too is a direct
target of Eklf (Fig. 8B).
We also performed a time course study of Bklf and Klf10
mRNA levels following induction. It was expected that indirect
target genes would exhibit a considerable lag phase before
being expressed. However, statistically significant increases in
Bklf exon 1b and Klf10 transcripts were detected after only 2
and 4 h postinduction, respectively, thus providing further ev-
idence that the Bklf and Klf10 genes are direct targets of Eklf
(Fig. 8C and D).
FIG. 5. Both Bklf promoters are less active in E14.5 Eklf/ murine fetal liver. Analysis of the two Bklf transcripts in E14.5 littermate Eklf/,
Eklf/, and Eklf/ fetal livers was performed by quantitative real-time RT-PCR. (A) Bklf exon 1a transcripts. (B) Bklf exon 1b transcripts.
(C) Total Bklf transcripts: Bklf-specific primers were designed to amplify a region spanning the exon 4/5 boundary. Bklf mRNA levels were
normalized to 18S rRNA levels.
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Eklf-ER binds endogenous Bklf promoters 1a and 1b in B1.6
cells. To confirm that Eklf activates Bklf by direct binding, we
conducted ChIP assays using Eklf antiserum to detect the
presence or absence of Eklf-ER at the Bklf promoters. ChIP
material was obtained from uninduced and tamoxifen-induced
B1.6 cells. As a positive control, Eklf-ER was detected at the
-major globin promoter, a known target of Eklf (Fig. 9E).
Upon induction of the cells, Eklf-ER was found to associate
FIG. 6. Eklf transactivation assays of the Bklf promoters in SL-2 cells. Zero, 10, 50, or 100 ng pPac-Eklf (supplemented to 100 ng with pPac)
was cotransfected with 1 g pGL4.10[luc2] reporter vector containing fragments of Bklf promoter 1a (189 to 89 or 532 to 89) (A) or varied
lengths (225 to 61, 129 to 61, 121 to 61, or 35 to 61) of Bklf promoter 1b (B). Firefly luciferase activity has been expressed as
activation above that observed for cells transfected with each reporter vector and pPac alone. (A and B) Cell lysates were assayed for firefly
luciferase activity 48 h posttransfection. Reporter activity has been normalized to Renilla luciferase levels. , P  0.05 compared to pGL4.10[luc2]-
empty cotransfected with 10, 50, or 100 ng pPac-Eklf as appropriate (paired Student’s t tests). , P  0.0005 and , P  0.05 compared to
pGL4.10[luc2]-Bklfprom1b(12961) cotransfected with 50 ng and 100 ng pPac-Eklf, respectively (paired Student’s t tests). (C) EMSA analysis
demonstrating that Eklf binds in vitro a CACCC box present in Bklf promoter 1b. Nuclear extracts were obtained from mock-transfected (lane 1)
and Eklf-overexpressing (lanes 2 to 3) COS cells. Nuclear extracts were allowed to bind to a radiolabeled probe containing the Bklf promoter 1b
CACCC box in the presence of either anti-Eklf (lane 3) or preimmune serum (lanes 1 and 2). RLU, relative light units.
FIG. 7. Bklf exon 1b and Klf10 transcripts are upregulated in the presence of Eklf. (A) Klf mRNA levels in B1.6 cells that were harvested 48 h
following induction with either 100 nM tamoxifen or with ethanol (0.0001%) as a control. (B) Klf10 transcript levels in Eklf/, Eklf/, and Eklf/
fetal livers. All mRNA levels were determined by quantitative real-time RT-PCR and normalized to 18S rRNA levels.
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with Bklf promoter 1b. No Eklf-ER was detected in negative
control regions: the nectin gene and a region 10 kb upstream of
the Bklf locus (Fig. 9B to D). Interestingly, Eklf-ER was also
detected at Bklf promoter 1a following induction of the cells
(Fig. 9A). This was somewhat unexpected given that no Bklf
transcripts from promoter 1a were observed in induced B1.6s
(Fig. 9A). Nonetheless, it is consistent with the previous ob-
servation that transcripts containing Bklf exon 1a are reduced
in Eklf-null fetal liver (Fig. 5A).
DISCUSSION
Many erythroid genes utilize alternative promoters to
achieve complex expression patterns (81). In particular, several
genes involved in the heme biosynthesis pathway, including
ALAD, PBGD, and UROS, possess an upstream housekeeping
promoter that enables widespread expression and a down-
stream promoter that is active in erythroid cells (2, 3, 16, 43).
Similarly, the genes encoding the transcription factors p45
Nf-e2 and Gata-2 each have dual promoters with housekeeping
and erythroid roles (57, 59, 65). We have shown here that
murine Bklf is another erythroid gene that is regulated by at
least two promoters that exhibit different expression profiles
but produce transcripts encoding identical proteins.
Transcripts containing exon 1a were readily detected by RT-
PCR in all tissues examined, thus suggesting that the upstream
promoter (1a) is widely active. In this sense, it can be consid-
ered a housekeeping promoter that allows Bklf expression in
both erythroid and nonerythroid cells and tissues. Promoter 1a
is GC rich, a trait which is characteristic of promoters which
generate ubiquitous transcripts (15, 73, 93). In addition, oligo-
nucleotide-cap cDNA analysis reveals that promoter 1a has
multiple transcriptional start sites spread over a region of ap-
proximately 300 bp. It is well established that most genes ex-
hibit some fluctuation in their start points of transcription (79).
However, this phenomenon has been noted to be particularly
pronounced for GC-rich, housekeeping promoters that lack a
TATA box, as is the case for Bklf promoter 1a (13, 15).
In contrast, the novel downstream promoter 1b is active
primarily in hematopoietic tissues, such as the fetal liver, adult
spleen, and bone marrow and in erythroid cells, such as the
tamoxifen-induced B1.6 erythroblast line and MEL cells. In
contrast to transcripts containing exon 1a, mRNA containing
exon 1b was barely detected in tissues such as the liver and
skeletal muscle and was undetected in the brain. This result
suggests that, unlike promoter 1a, promoter 1b does not ex-
hibit a widespread basal level of activity. Consistent with its
FIG. 8. Bklf and Klf10 are directly activated by Eklf-ER. (A and B) B1.6 cells were exposed to cycloheximide (CHX) 30 min before induction
with tamoxifen and were harvested for RNA 8 h thereafter. Bklf exon 1b levels (A) and Klf10 mRNA levels (B) were determined by quantitative
real-time RT-PCR. (C and D) B1.6 cells were harvested at numerous time points after tamoxifen induction in the absence of cycloheximide. Again,
Bklf exon 1b levels (C) and Klf10 mRNA levels (D) were determined by quantitative real-time RT-PCR. In all cases, 18S rRNA levels were used
for normalization. *, **, and ***, P  0.05 (paired Student’s t test, compared to ethanol control or 0-h time point as appropriate).
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restricted activity, promoter 1b is noticeably less GC rich than
promoter 1a and does not resemble a typical housekeeping
promoter. It lacks a canonical TATA box, although it does
have an AT-rich element (TAAAAT) at 26 to 21. In ad-
dition, promoter 1b contains a motif that perfectly fits the
consensus of a downstream promoter element (28 A/G G
A/T C/T G/A/C 32) (47).
In concordance with its erythroid cell-restricted activity, we
have demonstrated here that Bklf promoter 1b is directly ac-
tivated by Eklf-ER in the B1.6 erythroid cell line. It is also
highly dependent on Eklf in murine fetal liver. This depen-
dence presumably accounts for the expression of transcripts
containing exon 1b being restricted to hematopoietic tissues,
such as the spleen and bone marrow, where Eklf is known to be
present (56). A 190-bp region of promoter 1b (129 to 61)
is strongly activated by Eklf in reporter assays with SL-2 cells.
This region contains three elements that fit the Eklf-binding
consensus. One of these elements (centered around 126) is
identical to the proximal CACCC box of the -major globin
promoter (32), albeit on the opposite strand, and is bound by
Eklf in vitro. Deletion of this CACCC box leads to a significant
reduction in the activation of the promoter by Eklf. Interest-
ingly, in Bklf promoter 1b, this CACCC box is flanked by a
motif that fits the Gata-binding consensus of 5-A/T GATA
A/G-3 (25, 54, 89). Gata-1 has previously been noted to phys-
ically interact with Eklf and to synergistically potentiate tran-
scriptional activation (55).
The ubiquitously active promoter 1a also appears to be de-
pendent on Eklf in erythroid cells. Exon 1a transcripts are
markedly reduced in the Eklf/ fetal liver. In B1.6 cells,
Eklf-ER is detected at promoter 1a by ChIP analysis; however,
no resultant transcripts in B1.6 cells are detected. It is possible
that other factors that are required for promoter 1a activity are
absent in the cells, perhaps as a side effect of the immortaliza-
tion process. While the 189 to 89 fragment of promoter 1a
displays only mild activation by Eklf in SL-2 cells, an extended
region (532 to 89) is strongly activated. This result suggests
that CACCC boxes between 532 and 189 contribute signif-
icantly to Eklf activation of Bklf promoter 1a.
Despite its dependence on Eklf in erythroid cells, Bklf pro-
moter 1a is also comparably active in nonerythroid tissues
where Eklf is absent, such as lung, gastrointestinal, and white
adipose tissues. This implies that in nonerythroid tissues, pro-
moter 1a may be bound by factors which are capable of sub-
stituting for Eklf and which are sufficient to activate transcrip-
tion. Indeed, it is possible that other members of the Klf family
may utilize Eklf’s cognate binding site(s) in promoter 1a and
thus drive Bklf expression in nonerythroid tissues. Within the
family, lung Kru¨ppel-like factor (Lklf/Klf2) and gut-enriched
Kru¨ppel-like factor (Gklf/Klf4) are the most highly related to
Eklf (9, 21, 38, 78, 85) and, hence, these two factors are suit-
able candidates to assume such a compensatory role. This
hypothesis is interesting and raises the possibility that pro-
moter 1a and, by inference, other typical GC-rich housekeep-
ing promoters, may be ubiquitously expressed by virtue of
being dependent on some tissue-restricted Klfs in some tissues
and other Klfs in other tissues, rather than being dependent
exclusively on ubiquitous GC-box-binding proteins, such as
FIG. 9. Eklf ChIP at the two Bklf promoters. ChIP material was extracted from B1.6 cells that were induced with tamoxifen or ethanol (control).
Chromatin was immunoprecipitated using an Eklf antibody (denoted by “”) or preimmune serum (). Primers used for real-time PCR
quantification were targeted against Bklf promoter 1a (A), Bklf promoter 1b (B), a control region 10 kb upstream of the Bklf locus (C), the nectin
promoter (D), and the -major globin promoter (E).
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Sp1. However, if compensation by other Klfs is occurring, the
question of why promoter 1b is not similarly active in non-
erythroid tissues is raised. A possible explanation for this is
that promoter 1b may contain sequence elements other than its
Eklf-binding site(s) which are bound exclusively by erythroid
factors which, in turn, are crucial for transcriptional activation,
for instance, Gata-1.
Eklf has been found to function predominantly as an acti-
vator, whereas Bklf is generally a repressor. Both proteins have
also been shown to bind in vitro to an overlapping set of
CACCC elements found in erythroid promoters, such as those
of the -globin, carbonic anhydrase I, Gata-1, Pbgd, and pyru-
vate kinase genes as well as in globin locus control region
DNase hypersensitive sites (20). Therefore, given the opposing
roles of the proteins in transcriptional regulation, the most
likely consequence of Eklf’s activation of Bklf is that it serves
to temper Eklf’s stimulatory effects. That is to say that Bklf
upregulation inhibits the unbridled activation of Eklf’s target
genes. In support of this idea, reporter assays conducted with
SL-2 cells have shown that Bklf can silence Eklf activation of a
CACCC-containing promoter (84). There is also evidence that
Bklf promoter 1b is itself subject to autorepression. In B1.6
cells, Bklf exon 1b levels are higher in the cycloheximide-
treated cells than in untreated cells (compare Fig. 8A and C at
the 8-h time point). This is one possible consequence of un-
checked Eklf-mediated activation.
Such transcriptional antagonism has been observed among
members of the Klf family in reporter assays using a number of
promoters, including those of the Ap-2 (36), cytochrome
p4501A1 (Cyp1a1) (35, 39, 40, 95), and cyclin D1 (48, 60, 74,
96) genes. In particular, Klf4 and Klf5 have been shown to
exhibit opposing effects at a number of promoters in transient
transfection experiments. Klf4 represses while Klf5 activates
the smooth muscle SM -actin (51) and SM22- (1) promoters
as well as the cyclin D1 (60, 74) and laminin-1 (69) promoters.
It is possible that, similar to Klf4 and Klf5, Eklf and Bklf may
demonstrate contrasting functions in order to fine-tune the
expression of a set of common target genes. Future studies will
endeavor to identify target genes of Bklf which are either
shared with Eklf or which are distinct, due to subtle differences
in the binding preferences of the two transcription factors.
Further evidence of cross-regulation within the Klf family
comes from the observation in this study that Eklf also upregu-
lates Klf10 expression in the fetal liver and in tamoxifen-
treated B1.6 erythroblasts. Klf10 is a negative regulator of cell
cycle progression (11, 37, 82). Its induction is therefore con-
sistent with the reduced proliferation of B1.6 cells observed
after Eklf-ER induction. Interestingly, the human KLF10 gene
contains two alternative promoters (26). The upstream pro-
moter is widely active, while the function of the downstream
promoter is unclear (26). It is possible that these alternative
promoters are conserved in the mouse and that one or both
may be responsive to Eklf.
The results presented here provide evidence that the Klf
family is subject to internal hierarchical regulation, with Eklf
activating the Bklf and Klf10 genes in erythroid cells. Other
examples of cross-regulation and autoregulation have also
been inferred from transient transfection experiments and
work with cell lines. Klf8 binds and represses the Klf4 promoter
(92). In addition, reporter assays have demonstrated that Klf4
is able to activate its own promoter, while Klf5 represses it
(22). Further indirect evidence of hierarchical regulation
comes from observations of concomitant changes in Klf ex-
pression during lymphocyte differentiation. For example, Klf2,
Bklf, and Klf4 are expressed in resting B lymphocytes and are
downregulated upon activation through the B-cell receptor
(28, 30, 94). Similarly, Eklf, Klf2, and Bklf are expressed in
quiescent T cells and are downregulated following activation
(83, 94). Another member of the KLF family, KLF13, is also
regulated during T-cell activation, albeit at a posttranscrip-
tional level. As such, KLF13 protein, but not mRNA, is up-
regulated during T-cell activation (62, 76). Taken together with
the results presented here, these studies allude to a complex
web of hierarchical regulation which presumably functions to
finely adjust the expression patterns of downstream target
genes.
The widespread expression of Bklf, combined with potential
redundancy by other members of the Klf family, has compli-
cated interpretations of the Bklf-null mice data (not shown).
However, although determination of the biological role of Bklf
has been difficult, the results presented here provide strong in
vivo evidence that Bklf is dependent on the erythroid transcrip-
tional activator Eklf. Eklf has been shown to be crucial for
erythropoiesis and directly binds to and regulates numerous
erythroid promoters, including that of the adult -globin gene.
The observation that Bklf has two Eklf-dependent promoters,
of which one appears to be active predominantly in erythroid
tissues, strongly suggests that Bklf performs an erythroid role
in vivo. Investigations on whether Bklf represses genes acti-
vated by Eklf in vivo are continuing.
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